What to Do When a Claimant Requests GLP-1 Medications
Navigate weight loss medication requests in the claims context
Published: 3 April 2026 | Updated: 3 April 2026
The GLP-1 Phenomenon in Claims
Glucagon-like peptide 1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy), are increasingly requested by claimants seeking weight loss. These medications are legitimately approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), and they're highly effective. However, in the insurance claims context, GLP-1 requests often fall outside the scope of injury-related treatment. A claimant five years post-injury with diabetes now seeking GLP-1 for weight loss may have a clinical justification, but it's distinct from claim-specific recovery needs. Your challenge is distinguishing genuine injury-related indications from requests that, while medically appropriate, aren't the insurer's responsibility. This article provides a framework to evaluate GLP-1 requests fairly and make informed coverage decisions.
GLP-1 Receptor Agonists: Mechanism and Indications
GLP-1 agonists activate glucagon-like peptide 1 receptors, enhancing insulin secretion, slowing gastric emptying, and increasing satiety. FDA-approved agents include semaglutide (Ozempic for diabetes, Wegovy for weight management), tirzepatide (Mounjaro, dual GLP-1/GIP agonist), and others. Dosing is typically subcutaneous weekly injections.
Approved Indications
- Type 2 diabetes: Approved; improves glycemic control and associates with cardiovascular and weight loss benefits
- Chronic weight management: FDA-approved; indicated for BMI 30 or higher, or BMI 27 or higher with weight-related comorbidities
- Cardiovascular risk reduction: Some GLP-1 agents reduce cardiovascular events in diabetes
GLP-1 Requests in Claims: Common Scenarios
| Scenario | Context | Your Response |
|---|---|---|
| Claimant with injury, pain-related weight gain (10kg over 2 years), requests GLP-1 to support return-to-work | Weight gain is secondary to injury (reduced mobility, pain-related inactivity). Loss could genuinely support function and work-return. | Consider funding if dietitian and physiotherapy have been optimized first and weight loss would meaningfully improve work capacity. Request clinical justification linking weight loss to rehabilitation goals. |
| Claimant with pre-injury type 2 diabetes, now seeking GLP-1 for weight management | Diabetes existed pre-injury; weight management is general health, not injury-specific. | Generally not your responsibility. Direct claimant to primary health funding (Medicare, private health). Exception: if injury has worsened diabetes control or accessibility to management. |
| Claimant with new-onset diabetes secondary to injury (e.g., steroid-induced or physical inactivity-induced), requests GLP-1 | Diabetes is injury-related. GLP-1 supports management of injury-related complication. | Reasonable to consider funding. Prioritize lifestyle intervention and less costly agents first (metformin); escalate to GLP-1 if glycemic control inadequate. |
| Claimant five years post-injury, off medication, requesting GLP-1 for personal weight loss goal unrelated to claim | No injury-claim nexus. General health management. | Decline. Insurer responsibility ended. Direct to primary health funder. |
Questions to Ask Before Funding GLP-1
When a claimant requests GLP-1, ask yourself and your claims team:
- Is there a documented diagnosis of type 2 diabetes or a weight-related medical condition that's injury-secondary? (Not just general obesity.)
- Has conservative management (diet, exercise, first-line medications like metformin) been trialed and failed? (GLP-1 should not be first-line unless specific contraindications.)
- Is weight management directly linked to rehabilitation outcomes or return-to-work capacity? (Weight loss should meaningfully support recovery, not just meet aesthetic goals.)
- Does the claimant have access to other funding sources for weight management? (Medicare may cover GLP-1 for type 2 diabetes; patient may have private insurance.)
- Is GLP-1 the most cost-effective option, or are alternatives justified first? (Cost of GLP-1 is significant; ensure proportionality to benefit.)
- How long is GLP-1 intended to continue? (Long-term indefinite funding is a major commitment; clarify endpoint.)
Clinical Appropriateness Assessment
Before Approving GLP-1, Verify
Step 1: Confirm diagnosis. If diabetes, request HbA1c or glucose levels. If weight management, document current BMI and comorbidities justifying treatment.
Step 2: Confirm conservative management trial. Request documentation of dietitian consultation, exercise program, and first-line medication trial (metformin for diabetes). Ensure these have been optimized before GLP-1.
Step 3: Link to injury and recovery. Request treating doctor explanation: how does GLP-1 support injury recovery or work-return? If unrelated to injury, it may not be claimant's responsibility.
Step 4: Establish duration and endpoint. Request plan for how long GLP-1 will continue. Is the goal temporary (e.g., 6 to 12 months to achieve weight loss target supporting return-to-work) or indefinite chronic management?
Step 5: Cost-effectiveness check. GLP-1 cost is substantial (approximately $100 to 300 per month). Confirm benefit exceeds cost and alternatives have been exhausted.
Coverage Decision Framework
Approve GLP-1 if:
- Documented type 2 diabetes (injury-related or pre-existing managed as part of injury recovery)
- First-line agents and lifestyle modification optimized without adequate glycemic control
- Weight loss directly supports functional improvement or return-to-work goals
- Limited alternative funding sources available
- Defined duration and exit criteria documented
Decline or Defer GLP-1 if:
- Request is for general weight loss unrelated to injury recovery
- Conservative management not trialed or documented
- Weight loss has no clear nexus to functional recovery or rehabilitation
- Claimant has alternative funding sources (Medicare, private insurance) available
- More cost-effective alternatives not yet exhausted
- Claim is closed or substantially resolved and GLP-1 is for general health, not recovery
Shared Funding Approach
In some cases, GLP-1 may be appropriate but shared responsibility between funder sources is reasonable. For example, a claimant with injury-related diabetes may have Medicare fund the diabetes-related component while the insurer funds rehabilitation-specific optimization (physiotherapy to support exercise, dietitian visits). This avoids duplication and clarifies each funder's role.
Communicating the Decision to Claimants
Whether you approve or decline, explain your decision clearly:
- If approved: "Your request for GLP-1 is approved because it directly supports your rehabilitation. Here are the terms: duration is [6 months], funded through [insurer], with review at [date]. You'll also continue physiotherapy and dietitian support."
- If declined: "While GLP-1 is medically appropriate for your situation, it's not within the scope of injury-related treatment we fund. Your GP and Medicare may cover this. We'd be happy to support other rehabilitation goals like physiotherapy or pain management."
Regulatory and Ethical Considerations
Be aware that GLP-1 availability and cost is evolving. Regulatory status may differ between AU and NZ. Some schemes (workers compensation, CTP) have specific guidance on novel agents. Consult your legal and clinical advisors on scheme-specific rules before making GLP-1 coverage decisions.
Common Pitfalls to Avoid
- Funding GLP-1 for general obesity without injury link: This shifts insurer responsibility into general health management, appropriate for other funders.
- Approving without conservative management trial: GLP-1 should follow lifestyle and first-line medication, not precede it.
- Indefinite approval without review: Always define duration and endpoint. Chronic disease management should eventually transfer to primary care.
- Ignoring cost proportionality: GLP-1 is expensive. Ensure benefit justifies cost relative to alternatives.
- Failing to coordinate with other funders: If Medicare or private insurance can fund, clarify roles to avoid duplication.
Has your claimant requested GLP-1 and you're unsure about coverage?
IMM's medication reviews assess whether GLP-1 is clinically appropriate and injury-related, verify that conservative management has been optimized, and help clarify responsibility boundaries between injury and general health funders. We support your claims team in making fair, evidence-based decisions.
Request a Medication Review
